Transient viremia in HIV-infected patients and use of plasma preparation tubes

Clinical Infectious Diseases

Volumn 41, Issue 11, 2005, Pages 1671-1674

  Stosor, Valentina ^a   Palella Jr , Frank J ^a   Berzins, Baiba ^a   Till, Michele ^a   Leake, Angel ^a   Chmiel, Joan S ^a   Murphy, Robert L ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EDETIC ACID; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DATA BASE; FEMALE; FEVER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; LABORATORY TEST; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PLASMA; PLASMA PREPARATION TUBE; PRIORITY JOURNAL; TUBE; VIREMIA; VIRUS LOAD;

ADULT; ARTIFACTS; BLOOD SPECIMEN COLLECTION; HIV INFECTIONS; HUMANS; MIDDLE AGED; VIRAL LOAD; VIREMIA;

EID: 28044465952     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/498025     Document Type: Article

References (8)

1. BD Vacutainer PPT Plasma Preparation Tube [product circular]. Available at http://www.bd.com/vacutainer/pdfs/bd_ppt_VDP40081.pdf. Accessed 11 March 2005.
2. Holodniy M, Mole L, Yen-Lieberman B, et al. Comparative stabilities of quantitative human immunodeficiency virus RNA in plasma from samples collected in VACUTAINER CPT, VACUTAINER PPT, and standard VACUTAINER tubes. J Clin Microbiol 1995; 33:1562-6.
3. Holodniy M, Rainen L, Herman S, Yen-Lieberman B. Stability of plasma human immunodeficiency virus load in VACUTAINER PPT plasma preparation tubes during overnight shipment. J Clin Microbiol 2000; 38:323-6.
4. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK. Guidelines for using antiretroviral agents among HIV-infected adults. The Panel on Clinical Practices for Treatment of HIV. Ann Intern Med 2002; 137:381-433.
5. Aberg JA, Gallant JE, Anderson J, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2004; 39:609-29.
6. United States Department of Health and Human Services, United States Food and Drug Administration Center for Drug Evaluation and Research. Guidance for industry: antiretroviral drugs using plasma HIV RNA measurements-clinical considerations for accelerated and traditional approval/Center for Drug Evaluation and Research. Rockville, MD: Center for Drug Evaluation and Research, 2002. Available at http: //www.fda.gov/cder/guidance/5879dft.htm. Accessed on 11 March 2005.
7. Squires K, Lazzarin V, Delfraissy J, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004; 36:1011-9.
8. 2EDTA tubes with the Roche AMPLICOR HIV-1 MONITOR test, vl .5 UltraSensitive and Standard specimen processing procedures. Franklin Lakes, NJ: BD Diagnostics, 2005. Available at http://www.bd.com. Accessed on 11 March 2005.